NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 16, Issue 3, Pages 569-581
Publisher
Wiley
Online
2011-05-20
DOI
10.1111/j.1582-4934.2011.01343.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neuroblastoma: Therapeutic strategies for a clinical enigma
- (2010) Shakeel Modak et al. CANCER TREATMENT REVIEWS
- Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
- (2010) F. Navid et al. CURRENT CANCER DRUG TARGETS
- IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA
- (2010) Stephan Kloess et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion
- (2010) Sabine Huenecke et al. JOURNAL OF IMMUNOTHERAPY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
- (2010) Linda S. Sorkin et al. PAIN
- 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells
- (2009) B. Altvater et al. CLINICAL CANCER RESEARCH
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
- (2009) Katherine K. Matthay et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy for neuroblastoma: Turning promise into reality
- (2009) Juliet C. Gray et al. PEDIATRIC BLOOD & CANCER
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial
- (2008) Andrew DJ Pearson et al. LANCET ONCOLOGY
- Natural killer cell–directed therapies: moving from unexpected results to successful strategies
- (2008) Magali Terme et al. NATURE IMMUNOLOGY
- Up on the tightrope: natural killer cell activation and inhibition
- (2008) Lewis L Lanier NATURE IMMUNOLOGY
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
- Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group
- (2008) Peter E. Zage et al. PEDIATRIC BLOOD & CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now